Aktis Oncology
3 known investors
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors. The company serves oncology patients and healthcare providers in the cancer care sector.
BiotechHealthtechMedical Devices
Founders & leadership
TF
Todd FoleyCo-founder and Chairman
PB
Patrick BaeuerleCo-founder & Advisor
Investors · 3
In the news
- Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Resultsglobenewswire.com · 2026
- Aktis raises $318M in 2026’s first biotech IPO | BioPharma Divebiopharmadive.com · 2026
- Aktis raises $175M to fuel radiopharma drug development | BioPharma Divebiopharmadive.com · 2024
- Aktis Oncology raises millions in funding bringing total to $161MNlabiotech.eu · 2022
- AKTIS ONCOLOGY RAISES $84 MILLION TO ADVANCE NOVEL TARGETED ALPHA RADIOPHARMACEUTICALS - Aktisaktisoncology.com · 2022
- Aktis Oncology Raises $72M in Series A Financing - FinSMEsfinsmes.com · 2021